Tinea & Dermatophytosis (Ringworm)

Overview & Definition

Tinea (dermatophytosis, ringworm) is one of the commonest skin conditions in the world — its lifetime prevalence approaches a quarter of the global population, and in tropical and subtropical regions, including India and South Asia, it has reached epidemic proportions.^[10] It is caused by a specialised group of keratinophilic moulds called dermatophytes that digest keratin in the stratum corneum, hair shafts, and nails for nutrition, and is therefore confined to keratinised tissue — it does not invade living cells and does not infect mucosa (a feature that immediately separates it from candidiasis).^[1]

The genus dermatophyte is divided into three genera — Trichophyton, Microsporum, and Epidermophyton — distinguished by their tissue tropism and, in part, by their ecological source (anthropophilic, zoophilic, or geophilic). The clinical lesion they produce is one of the most instantly recognisable in medicine: the annular, erythematous, scaly plaque with a raised, advancing scaly border and central clearing that gives the condition its popular name, ringworm. Lesions are named by the site they occupy (tinea corporis for body, cruris for groin, pedis for feet, capitis for scalp, unguium for nails, manuum for hand, faciei for face, barbae for beard) and each site carries its own differential diagnosis, treatment duration, and prognosis.^[1][2]

The two clinical skills that decide almost every tinea question — at viva, in the MCQ, and at the bedside — are confirming the diagnosis with a potassium hydroxide (KOH) mount of the active border (avoiding the catastrophic error of mistaking tinea for eczema and treating it with topical corticosteroids), and knowing when topical therapy is sufficient versus when oral antifungal therapy is mandatory. Tinea capitis and onychomycosis always require oral therapy; so do extensive, recurrent, or steroid-modified disease; so do Majocchi granuloma and immunosuppression.^[2][3] Three scenarios deserve particular vigilance: the kerion (a boggy, tender, purulent inflammatory tinea capitis in a child) which is an emergency requiring oral antifungal plus oral corticosteroid — and which is never incised like an abscess; the tinea incognito that arises from misuse of fixed-dose corticosteroid-antifungal-antibacterial creams (the Indian AAA syndrome — Abuse, Application, Addiction), an epidemic that produces atypical, non-annular, infiltrative plaques that mimic eczema, psoriasis, rosacea, and lupus; and the two-feet-one-hand syndrome in which bilateral tinea pedis is the silent reservoir for a unilateral tinea manuum.^[10][11][12]

Classification

Tinea is classified on two axes — the body site infected (which dictates the clinical name and the differential diagnosis) and the causative genus and ecological origin (which dictates the inflammatory response and the choice of antifungal). Both must be mastered. ^[1]

Classification by site

1. Tinea corporis — body; the classic annular ringworm with active scaly border and central clearing.
2. Tinea cruris — groin ('jock itch'); symmetric, sharply marginated, spares the scrotum.
3. Tinea pedis — athlete's foot; three patterns: interdigital (toe-web scaling, maceration; commonest), moccasin (diffuse hyperkeratotic plantar scale, often T. rubrum), vesiculobullous/inflammatory (vesicles on instep, often zoophilic).
4. Tinea capitis — scalp; subtypes: black-dot (endothrix Trichophyton), grey patch (ectothrix Microsporum), kerion celsi (intense boggy inflammation, usually zoophilic), favus (T. schoenleinii, scutula, permanent alopecia).
5. Tinea unguium / onychomycosis — nails; patterns: distal lateral subungual (commonest), proximal subungual (think HIV), white superficial (T. mentagrophytes), endonyx, total dystrophic.
6. Tinea manuum — hand; typically unilateral; classically part of two-feet-one-hand syndrome.
7. Tinea faciei — face; often misdiagnosed as eczema, lupus, rosacea; KOH is mandatory.
8. Tinea barbae — beard; deep inflammatory nodules from zoophilic species.
9. Tinea incognito — steroid-modified tinea; atypical, non-annular, infiltrative; from misuse of topical corticosteroid combination creams. ^[1]

Epidemiology & Risk Factors

Tinea is among the most prevalent of all human skin conditions. Lifetime prevalence is in the range of 20 to 25 percent globally, and in tropical climates — especially India, South-East Asia, and sub-Saharan Africa — it has reached epidemic proportions in the last decade, driven by heat, humidity, dense urban living, occlusive clothing, and the catastrophic misuse of fixed-dose corticosteroid-antifungal-antibacterial creams.^[10][12]

The dominant species has shifted over decades. Trichophyton rubrum is now the global workhorse, responsible for most chronic tinea pedis, onychomycosis, tinea cruris, and the two-feet-one-hand pattern; T. mentagrophytes/interdigitale is a close second and is the species driving the emerging terbinafine resistance in India (the ITS genotype VIII clone, with mutations in the squalene epoxidase gene).^[12] In children, Microsporum species (M. canis from kittens and puppies, M. audouinii human-to-human) and Trichophyton tonsurans dominate tinea capitis; the species mix is regional and shifts over time.

The host and environmental risk factors cluster into environmental (heat, humidity, sweating, occlusive footwear and clothing, communal showers, swimming pools, gyms, contact sports — the term 'tinea gladiatorum' for wrestlers), host (diabetes mellitus, peripheral arterial disease, atopy, obesity, immunosuppression — HIV, transplant, chemotherapy, chronic corticosteroid), and occupational (military, athletes, miners, farmers, swimmers, animal handlers).^[2][3]

Tinea capitis is predominantly a disease of prepubertal children (peak ages three to seven years) and is rare after puberty — pubertal sebum is rich in fungistatic saturated fatty acids (sapienic acid) that inhibit dermatophyte growth.^[4] Animal reservoirs are the source of zoophilic species and the explanation for more inflammatory disease: Microsporum canis from kittens and puppies, Trichophyton verrucosum from cattle (kerion and inflammatory tinea barbae in farmers), T. mentagrophytes from rodents. Diabetics and immunocompromised patients are at markedly higher risk of extensive, recurrent, and atypical disease — a patient with recurrent tinea should be screened for diabetes (HbA1c) and HIV.^[3]

Pathophysiology

Dermatophytes are obligately keratinophilic fungi that live in the non-living, keratinised layer of the skin (stratum corneum), the hair shaft (cortex and cuticle), and the nail plate. They cannot survive in living tissue. Their defining metabolic feature is the secretion of keratinases and other proteases (subtilisins, metalloproteases) that break keratin down into peptides and amino acids the fungus can use as nitrogen and carbon sources.^[1] This single fact explains why tinea affects only skin, hair, and nails — and never mucosa, which is non-keratinised and bathed in antifungal defensins.

The three ecological classes — and why they matter clinically

Dermatophytes are classified ecologically by their natural reservoir, which predicts their inflammatory intensity and their epidemiology: ^[1]

• Anthropophilic (human-to-human) — e.g. Trichophyton rubrum, T. tonsurans, T. violaceum, Microsporum audouinii, Epidermophyton floccosum. These have co-evolved with humans and produce chronic, low-grade inflammation, large plaques, and high transmissibility in households and communal facilities. They are the principal drivers of recurrent tinea pedis, cruris, and onychomycosis.
• Zoophilic (animal-to-human) — e.g. Microsporum canis (dogs, cats), Trichophyton verrucosum (cattle), T. mentagrophytes (rodents), T. equinum (horses). These provoke an intense, often suppurative inflammatory response — kerion celsi, vesiculobullous tinea pedis, inflammatory tinea barbae — because the host immune system has not adapted to them. The inflammation is so intense it can self-limit the infection, but it also produces scarring alopecia in kerion.
• Geophilic (soil-dwelling) — e.g. Microsporum gypseum. Acquired from soil, rare, produces geographic, sporadic inflammatory lesions.^[1][3]

Why the plaque is annular with central clearing — the immune explanation

The classic ringworm pattern is a direct readout of the host immune response. Dermatophyte antigens (mannans, proteases) trigger a T-cell mediated delayed-type hypersensitivity reaction in the skin: keratinocytes release IL-1, IL-17, IL-8, and β-defensins, recruiting neutrophils and activated T-cells that clear the fungus.^[1] Clearance happens first in the centre of the plaque (where the infection is oldest and immunity is highest) and slowest at the advancing border (where hyphae are growing fastest into naive skin). The result is the annular plaque with central clearing and an active, scaly, advancing leading edge — the border is where the live hyphae are, which is why the KOH scraping is taken from the active border, not the centre.

Hair invasion patterns — endothrix vs ectothrix

When dermatophytes invade hair, the pattern of arthroconidial invasion is genus-specific and diagnostically useful: ^[1]

• Ectothrix — arthroconidia form a sheath around the outside of the hair shaft; hair breaks a few millimetres above the scalp, leaving a stump surrounded by a spore sheath. Classic of Microsporum species and some Trichophyton. Many ectothrix species (M. canis, M. audouinii, M. ferrugineum) fluoresce bright green under Wood's lamp because tryptophan metabolites (pteridine-like compounds) produced in the hair cortex emit at 365 nm.^[4]
• Endothrix — arthroconidia fill the inside of the hair shaft; the hair breaks flush with the scalp, leaving a black dot in the follicle. Classic of Trichophyton tonsurans, T. violaceum, T. soudanense, T. schoenleinii. Endothrix species do not fluoresce under Wood's lamp.
• Favic — hyphae and air spaces within the hair shaft; T. schoenleinii; produces the yellow cup-shaped scutulum of favus.^[4]

Mechanism of tinea incognito — why topical corticosteroids cause catastrophe

Topical corticosteroids cause tinea incognito through several converging mechanisms: (1) they suppress local cell-mediated immunity (T-cell activation, cytokine release, defensin production) that is the host's main defence against dermatophytes; (2) they reduce keratinocyte proliferation and impair barrier integrity, allowing deeper hyphal penetration; (3) they mask the inflammation that would otherwise prompt the patient to seek care — so the fungus proliferates unopposed for months; (4) they produce skin atrophy and telangiectasia that further breach the barrier and predispose to Majocchi granuloma (dermal invasion).^[10][11][12] Systemic absorption from extensive application of potent steroids (clobetasol, betamethasone) can produce iatrogenic Cushing's syndrome and hypothalamic-pituitary-adrenal suppression — documented in Indian patients using fixed-dose combination creams on large body surface areas.^[11]

Drug mechanism — the targets examiners test

Oral terbinafine is considered first-line systemic therapy for both tinea capitis and onychomycosis because it is well tolerated, effective, and inexpensive; emerging severe infections that do not improve with first-line topical or oral antifungals may require prolonged oral therapy and specialised diagnostic testing.^[3]

Clinical Presentation

The cardinal morphology of tinea is the annular, erythematous, scaly plaque with a raised, advancing scaly border (the active edge) and central clearing. Pruritus is variable — typically mild to moderate in anthropophilic infection, severe in zoophilic. The site-specific features are examinable in detail. ^[1]

Tinea corporis

Annular or arcuate, sharply demarcated, erythematous, scaly plaque on the trunk, limbs, or neck. The leading edge is raised, scaly, and may have tiny vesicles or pustules; the centre clears with post-inflammatory hyperpigmentation. Lesions may be single or multiple; they coalesce into polycyclic shapes. Pruritus is mild to moderate. The "active border" is the diagnostic clue and the site of KOH sampling.^[1]

Tinea cruris

Symmetric, sharply marginated, erythematous, scaly, half-moon-shaped plaques in the groin and inner upper thighs, extending onto the buttocks and lower abdomen. The scrotum is characteristically spared — a high-yield discriminator from candidal intertrigo, which involves the scrotum and produces satellite pustules.^[2] Common in obese males, athletes, and in hot, humid climates; frequently coexists with tinea pedis (auto-inoculation from feet to groin when dressing).

Tinea pedis

The most common dermatophytosis worldwide. Three clinical patterns:^[2]

• Interdigital — commonest; scaling, maceration, fissuring, and whitening of the toe-webs, especially the fourth interdigital space; usually T. rubrum or T. mentagrophytes. Pruritus and malodour. Complicated by secondary Gram-negative infection, cellulitis (especially in diabetics), and the dermatophytid (id) reaction.
• Moccasin (chronic hyperkeratotic) — diffuse, fine, silvery scale covering the plantar surface, sides of the foot, and heel, often unilateral; classically Trichophyton rubrum; frequently coexists with onychomycosis of the same foot. Topical therapy often fails because of poor penetration of the hyperkeratotic sole — oral therapy is frequently needed.
• Vesiculobullous (inflammatory) — vesicles, bullae, and erosions on the instep, often bilateral; usually zoophilic T. mentagrophytes; intense inflammation and pruritus; self-limiting but recurrent. ^[1]

Tinea capitis

Predominantly a disease of prepubertal children (peak ages three to seven years).^[4] Presentation varies with the species and the hair-invasion pattern:

• Black-dot tinea capitis — endothrix Trichophyton (T. tonsurans in the Americas/UK; T. violaceum in India and the Mediterranean); hairs break flush with the scalp, leaving black dots within patches of alopecia; scaling and occipital lymphadenopathy. Wood's lamp is negative (endothrix does not fluoresce).
• Grey-patch tinea capitis — ectothrix Microsporum (M. canis, M. audouinii); hairs break a few millimetres above the scalp, leaving a grey, scaly, slightly erythematous patch with short broken hairs; Wood's lamp shows bright green fluorescence.^[4]
• Kerion celsi — an intense, boggy, purulent, tender inflammatory mass on the scalp of a child, caused by a zoophilic or geophilic species (M. canis, T. verrucosum, T. mentagrophytes); posterior cervical lymphadenopathy, sinus formation, hair loss; may be misdiagnosed as a bacterial abscess — DO NOT INCISE.^[4]
• Favus — chronic infection by Trichophyton schoenleinii; yellow, cup-shaped scutula around hair follicles, mousy odour, diffuse scaling, and permanent scarring alopecia. Wood's lamp shows dull blue-green hair fluorescence. Now rare but a classic exam entity.^[4]

Tinea unguium / onychomycosis

A fungal infection of the nail plate, of which tinea unguium (dermatophyte, usually T. rubrum) is the commonest cause. The nail is thickened, discoloured (yellow-brown), dystrophic, with subungual hyperkeratosis and onycholysis.^[7][8] Patterns:

• Distal lateral subungual — commonest; starts at the distal-lateral nail fold and spreads proximally; T. rubrum.
• Proximal subungual — starts under the proximal nail fold; a marker of HIV immunosuppression (and now also biologic therapy); T. rubrum.
• White superficial — chalky white superficial nail plate; T. mentagrophytes (and non-dermatophyte moulds).
• Endonyx — lamellar splitting within the nail plate; T. soudanense.
• Total dystrophic — the entire nail plate is thickened, dystrophic, and destroyed. ^[1]

Toenails are far more commonly affected than fingernails; onychomycosis of the great toenail is a frequent reservoir for recurrent tinea pedis, cruris, and corporis.^[2]

Tinea manuum

Typically unilateral, dry, scaly, mildly erythematous, hyperkeratotic palm — the two-feet-one-hand syndrome when associated with bilateral tinea pedis (and often onychomycosis of both feet). Auto-inoculation from a chronic T. rubrum reservoir on the feet to the dominant hand that scratches is the mechanism.^[2]

Tinea faciei

Erythematous, often annular plaque on the face; frequently misdiagnosed as eczema, subacute cutaneous lupus erythematosus, rosacea, or contact dermatitis. Photosensitivity may be present. KOH is mandatory before any topical steroid is applied to a facial rash.^[3]

Tinea barbae

Deep inflammatory nodules, pustules, abscesses, and hair loss in the beard area of adult males; usually zoophilic T. verrucosum (from cattle) or T. mentagrophytes (from horses); common in farmers and animal handlers.^[3]

Tinea incognito (steroid-modified tinea)

The morphology is altered beyond recognition by the topical corticosteroid. The classic annular ringworm pattern is lost: plaques are non-annular, infiltrated, erythematous, scaly, with telangiectasia and atrophy; pustules may be present (deep folliculitis, Majocchi granuloma); the active scaly border is absent; the rash extends widely and chronically.^[10][12] It mimics eczema, psoriasis, rosacea, subacute cutaneous lupus erythematosus, contact dermatitis, and steroid-induced acne. The diagnosis is made by a high index of suspicion and a KOH mount — every patient with a chronic facial, groin, or body rash that is not behaving as expected should be asked about pharmacy-bought creams.^[10]

Atypical presentations in the immunocompromised

In HIV, transplant recipients, and patients on chronic corticosteroids or biologics, tinea can be extensive, rapidly spreading, atypical in morphology, and may invade deeply (Majocchi granuloma, dermal and subcutaneous invasion). Proximal subungual onychomycosis is an AIDS-defining indicator. Multiple sites (capitis + corporis + unguium + manuum simultaneously) suggest immunodeficiency.^[3]

Exam application bank (NEET-PG / INICET)

One-line answer

Tinea (dermatophytosis, ringworm) is a superficial fungal infection of keratinised tissue by dermatophyte moulds of three genera — Trichophyton (skin, hair, nails), Microsporum (hair, skin; many fluoresce green under Wood's lamp), and Epidermophyton floccosum (skin and nails, never hair). Dermatophytes secrete keratinases that digest keratin in the stratum corneum, hair shafts, and nails; they cannot invade living tissue. The clinical lesion is the annular, erythematous, scaly plaque with a raised, advancing, scaly border (active edge) and central clearing — the ringworm pattern — and is named by site: corporis, cruris, pedis (interdigital/moccasin/vesicular), capitis (black-dot/kerion/favus), unguium (onychomycosis), manuum, faciei, barbae, and incognito (steroid-modified). The diagnosis rests on clinical morphology + KOH mount of the active border showing branching septate hyphae, supp

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. ^[1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. ^[1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. ^[1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. ^[1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. ^[1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Tinea & Dermatophytosis (Ringworm).

Differential Diagnosis

The differential of tinea is wide because the annular scaly plaque is a final common pathway for many skin diseases. The high-yield strategy is to triage by morphology (annular, scaly, central clearing, active border), by site, and by KOH mount, then to confirm. ^[1]

^[1]

Site-specific differentials include: tinea capitis vs alopecia areata (smooth hairless patch with exclamation-mark hairs; no scale; KOH negative), seborrhoeic dermatitis, atopic dermatitis, and trichotillomania; onychomycosis vs psoriatic nail (pitting, oil-drop, onycholysis with skin psoriasis), lichen planus nail (brittle, dorsal pterygium), and traumatic nail dystrophy; tinea incognito vs asteatotic eczema, rosacea, SCLE, steroid-induced acne, and contact dermatitis.^[3][10]

Clinical & Bedside Assessment

The bedside assessment of suspected tinea has one non-negotiable step: the KOH mount of the active scaly border. Every other step serves to confirm the morphology, identify the source and reservoirs, and screen for complications and comorbidities.^[3]

Step 1 — recognise the morphology. Document whether the lesion is annular (ring-shaped) with a raised, advancing, scaly border and central clearing — the tinea signature. Note the site-specific pattern (interdigital toe-web maceration; moccasin plantar scale; boggy kerion; black-dot capitis; dystrophic nail; unilateral scaly palm). Examine the whole skin — never examine only the lesion — because tinea pedis is the silent reservoir for cruris, corporis, and manuum, and two-feet-one-hand syndrome is missed if you examine only the hand. ^[1]

Step 2 — perform the KOH scraping. Clean the lesion with 70% alcohol to remove surface contaminants. Using a #15 scalpel blade, scrape the active scaly border (the leading edge), collecting scale onto a glass slide. For tinea capitis, pluck affected hairs with forceps (or use a sterile toothbrush or hair-brush culture technique in children). Add 10 to 20% potassium hydroxide solution with dimethyl sulfoxide (DMSO) to speed keratin dissolution, coverslip, gentle heating (not boiling), and examine under 10x then 40x within 10 to 15 minutes.^[1][3]

Step 3 — interpret the KOH mount. Branching septate hyphae are the diagnostic centrepiece of dermatophyte infection — they cross cell walls regularly, branch at acute angles, and may show arthroconidia. In tinea capitis, look for endothrix (spores inside the hair shaft) or ectothrix (spore sheath around the shaft). In onychomycosis, irregular hyphal fragments and onycholytic debris are typical. A negative KOH does not exclude tinea — repeat, or proceed to culture. ^[1]

Step 4 — Wood's lamp examination. A 365 nm UV light in a darkened room. Microsporum species (M. canis, M. audouinii, M. ferrugineum) — bright green hair fluorescence (ectothrix); Trichophyton schoenleinii (favus) — dull blue-green; T. tonsurans, T. rubrum, T. violaceum — negative (endothrix). Useful in children for screening scalp infection, identifying asymptomatic carriers, and choosing the site of hair sampling.^[4]

Step 5 — dermatoscopy. Increasingly used. Tinea capitis: comma hairs (curved broken hair shafts) and corkscrew hairs. Onychomycosis: Morse-code sign (longitudinal white streaks with transverse bands). Tinea corporis: peripheral scaling with a leading edge. Dermoscopy helps distinguish tinea from eczema/psoriasis and select the biopsy site.^[3]

Step 6 — screen for source, reservoirs, and comorbidities. Ask about animal contacts (pets with alopecia, farm animals), household contacts with similar lesions, communal facility use (gyms, pools, dormitories), cosmetic cream use (the AAA syndrome — ask specifically about pharmacy-bought 'fairness' or 'ringworm' creams), and diabetes and HIV risk. In recurrent tinea, send HbA1c and HIV serology.^[3]

Investigations

The diagnostic algorithm: clinical suspicion → KOH mount of the active border (rapid, cheap, high yield). If KOH is negative but suspicion remains, repeat KOH or proceed to fungal culture. If tinea capitis is suspected, Wood's lamp first (helps choose the sampling site and screen contacts) then culture (essential to guide species-specific oral therapy, esp. Microsporum vs Trichophyton). If atypical or refractory, biopsy with PAS/GMS and consider PCR.^[1][3]

Adjunct investigations in recurrent or atypical tinea: HbA1c or fasting glucose (diabetes), HIV serology, CBC, and — before long-term oral therapy — LFTs and U&E (baseline for terbinafine/itraconazole monitoring). In suspected iatrogenic Cushing's from extensive topical steroid use, a morning cortisol and short synacthen test assess HPA-axis suppression.^[11]

Management — Resuscitation

^{[1] [3]}

Most tinea is managed in the outpatient setting. Three scenarios require urgent action: ^[1]

Kerion celsi — an emergency

A child with a boggy, tender, purulent scalp mass requires immediate systemic (oral) antifungal therapy — tinea capitis always needs systemic treatment because topical agents do not penetrate the root of the hair follicles deep within the dermis.^[4] Oral options include terbinafine, griseofulvin, itraconazole, and fluconazole, chosen by causative species: terbinafine is preferred for Trichophyton infections, while griseofulvin outperforms terbinafine for Microsporum.^[4][5] Adjunctive topical antifungal therapy reduces transmission of spores, and combined topical-plus-oral treatment may increase cure rates.^[4] Surgical drainage has no role — the fungus resides within hair follicles too deep for any local measure to reach.

Tinea incognito with iatrogenic Cushing's syndrome

Extensive misuse of potent topical corticosteroids — often alongside oral or parenteral steroids — on large body surface areas can cause systemic absorption and iatrogenic Cushing's syndrome, documented in an Indian cohort of 23 patients with superficial dermatophytosis: mostly extensive tinea cruris and corporis, treated for at least two months with potent topicals (clobetasol propionate, betamethasone valerate) plus systemic steroids, most often prescribed by unqualified practitioners, with profoundly suppressed serum cortisol in all of them.^[11] The preventive message is antifungal stewardship — avoiding combination antifungal–corticosteroid creams.^[11][3]

Safety-net counselling before discharge: treat all coexisting sites (especially tinea pedis as reservoir); wash towels, bedding, and clothing in hot water and dry thoroughly in sunlight; do not share towels or footwear; treat household and animal contacts; check HbA1c if recurrent; avoid pharmacy-bought corticosteroid combination creams.^[3]

Management — Definitive & Stepwise

The treatment ladder depends on the site and the severity. Localised skin disease responds to topical antifungals. Tinea capitis, onychomycosis, extensive/recurrent disease, tinea incognito, Majocchi granuloma, and immunosuppression all require oral antifungal therapy.^[2][3]

Topical antifungals — the workhorses for skin tinea

Application rules for topicals: apply to the lesion and 2 cm beyond the margin; apply once or twice daily as above; continue for 1 to 2 weeks after clinical resolution to prevent relapse; for tinea cruris extend to the inner thighs, gluteal fold, and lower abdomen; for tinea pedis interdigital treat the whole plantar surface and all toe-webs, not just the visible lesion.^[2]

Oral antifungals — when topicals are insufficient

Indications for oral therapy (must-know): (1) tinea capitis — always; (2) onychomycosis; (3) extensive or recurrent tinea corporis/cruris/pedis; (4) tinea incognito / steroid-modified tinea; (5) Majocchi granuloma; (6) immunosuppression; (7) tinea barbae.^[3]

^{[5] [7]}

Site-specific regimens

• Tinea corporis, cruris, pedis (interdigital), faciei — localised disease: topical antifungals are standard treatment.^[1] Multiple, extensive, deep, recurrent, chronic, or unresponsive lesions, or immunodeficiency: escalate to systemic antifungal therapy.^[1][3]
• Tinea pedis (moccasin) — oral therapy is usually used for chronic disease or when topical treatment has failed; pooled trial data favour terbinafine over griseofulvin for curing foot infection.^[2][9]
• Tinea capitis — always systemic (oral); topical agents alone are not recommended because they do not penetrate the hair follicle root.^[4] Choice is species-guided:^[5][6]
  • Trichophyton (T. tonsurans, T. violaceum): terbinafine (four weeks) is at least as effective as griseofulvin (eight weeks); clearly better for T. tonsurans.
  • Microsporum (M. canis, M. audouinii): griseofulvin is superior to terbinafine.
  • Adjunctive topical therapy reduces spore transmission and combined treatment may increase cure rates.^[4]
• Kerion celsi — see Resuscitation: urgent systemic antifungal therapy, species-guided.^[4]
• Onychomycosis (tinea unguium) — continuous oral terbinafine 250 mg or continuous itraconazole 200 mg has significantly greater odds of mycological cure than topical treatments; fluconazole and pulse regimens did not differ significantly from other options.^[7] Topical efinaconazole 10% solution outperforms vehicle for complete and mycological cure, and tavaborole 5% solution improves mycological cure — but complete-cure rates with topicals remain relatively low.^[8]
• Tinea incognito — recognise steroid-modified disease; avoid combination antifungal–corticosteroid creams (stewardship) and treat the dermatophytosis, systemically when extensive.^[3][10][11]
• Majocchi granuloma / hair-follicle involvement — oral antifungal therapy is indicated whenever hair follicles are involved.^[3]
• Tinea barbae — deep follicular involvement; manage like other follicular tinea with systemic therapy.^[3]

Adjunctive and preventive measures

• Wash towels, bed linen, and clothing in hot water and dry in sunlight (UV kills dermatophytes).
• Wear cotton socks and change them daily; rotate footwear; use antifungal powders (miconazole, tolnaftate) in shoes.
• Treat coexisting tinea pedis first — it is the reservoir for cruris, corporis, and manuum recurrence.
• Treat household contacts (asymptomatic capitis carriers; family members with shared tinea pedis) and pets (M. canis).
• Address obesity, sweating, occlusive clothing, diabetes, and HIV.
• Public health in India: ban/regulate fixed-dose corticosteroid-antifungal-antibacterial creams; pharmacist education; public awareness of the AAA syndrome.^[11]

Escalation triggers

• Failure of topical at 4 weeks → switch topical class or escalate to oral.
• Recurrence → oral + investigate diabetes and HIV + treat reservoirs and contacts.
• Suspected resistance (especially in Indian T. mentagrophytes genotype VIII) → culture and antifungal susceptibility; switch terbinafine to itraconazole.^[12]
• Kerion → oral antifungal + oral steroid; DO NOT incise.

Specific Subtypes & Scenarios

Tinea incognito and India's steroid-modified dermatophytosis epidemic deserves separate emphasis because it is now a major public health problem and a favourite exam topic.^[10][11][12] Patients randomly apply broad-spectrum steroid–antifungal–antibacterial creams containing potent corticosteroids (mainly clobetasol propionate) sold over the counter — a phenomenon Indian dermatologists describe as an epidemic of steroid-modified dermatophytosis, permitted to persist by misinterpretation and lax implementation of drug regulation.^[12] The steroid modifies the clinical picture into eczema-like and other mimicking patterns; in a prospective Indian series of one hundred suspected cases, pharmacists were responsible for 78 percent of tinea incognito cases and betamethasone dipropionate was the most common drug used.^[10] Extensive use — frequently with additional oral or parenteral steroids — has produced iatrogenic Cushing's syndrome with profoundly suppressed serum cortisol in Indian cohorts.^[11]

Tinea capitis in children is a particular scenario because it is always systemic (oral) therapy — topical agents alone are not recommended because they do not penetrate the hair follicle.^[4] The choice between griseofulvin and terbinafine is species-guided: the Fleece 2004 meta-analysis and the Chen 2016 Cochrane review agree that a two- to four-week course of terbinafine is at least as effective as six to eight weeks of griseofulvin for Trichophyton infections (and better for T. tonsurans), while griseofulvin is likely superior for Microsporum.^[5][6] The Bonifaz 2024 review addresses the practical problem of griseofulvin unavailability — oral terbinafine is the proposed replacement (and the preferred drug in elderly patients), with fluconazole discussed for paediatric use, though Microsporum infections remain a challenge.^[13] Adjunctive topical antifungal therapy reduces spore transmission and combined treatment may increase cure rates.^[4]

Kerion celsi — see Resuscitation. Always remember: boggy purulent scalp mass in a child + cervical lymphadenopathy = kerion, NOT a bacterial abscess; the treatment is systemic antifungal therapy, not incision.^[4]

Onychomycosis is a chronic, relapsing scenario that frustrates patients and clinicians. In the Gupta 2020 network meta-analysis of 77 randomised trials, continuous terbinafine 250 mg and continuous itraconazole 200 mg had significantly greater odds of mycological cure than topical treatments, whereas fluconazole and pulse regimens did not differ significantly from other options.^[7] Topical efinaconazole 10% solution outperforms vehicle for complete and mycological cure and tavaborole 5% solution improves mycological cure, but complete-cure rates with topical treatments are relatively low overall.^[8]

Complications & Pitfalls

Disease-related complications include secondary bacterial infection (impetiginisation, cellulitis, lymphangitis — especially in diabetics with tinea pedis, leading to diabetic foot ulcer), Majocchi granuloma (deep granulomatous folliculitis from dermal dermatophyte invasion after shaving, trauma, or topical steroid use), kerion scarring alopecia (permanent hair loss from follicular destruction if treatment is delayed), onychomycosis nail dystrophy (permanent nail deformity, pain, mobility impairment), post-inflammatory hyperpigmentation, and the dermatophytid (id) reaction.^[3]

The dermatophytid (id) reaction is a symmetric, sterile, vesicular or eczematous eruption on the hands, fingers, or forearms triggered by intense inflammation at a distant primary site (typically inflammatory tinea pedis or kerion). It is a hypersensitivity reaction to circulating fungal antigens; the lesions themselves are KOH-negative. Treatment is of the primary tinea (with oral antifungal); symptomatic treatment with topical corticosteroid for the id reaction itself is acceptable. Recognising the id reaction prevents the mistake of treating the hands (which are sterile) as primary tinea.^[3]

The single most dangerous pitfall is misdiagnosis of tinea as eczema and treatment with topical corticosteroids — producing tinea incognito, deeper invasion (Majocchi granuloma), eventual recalcitrance, and (in extensive use) iatrogenic Cushing's syndrome.^[10][11] The corollary: every pruritic annular plaque should have a KOH mount before a topical corticosteroid is prescribed.

Misdiagnosis of kerion as a bacterial abscess is the second great pitfall. Incision and drainage does not cure the fungus (which is in the hair shaft), causes additional scarring, delays antifungal therapy, and prolongs alopecia.^[4]

Drug-related adverse effects of long-term oral antifungals:

• Terbinafine: hepatotoxicity (rare but serious), ageusia (taste loss, often reversible), neutropenia, drug interactions via CYP2D6 (reduce dose of tricyclics, beta-blockers, SSRIs). Monitor LFTs at baseline and 6 weeks.
• Itraconazole: hepatotoxicity, negative inotropic effect (avoid in heart failure), hypokalaemia, major CYP3A4 drug interactions (rhabdomyolysis with statins, bleeding with warfarin, sedation with benzodiazepines, oedema with calcium channel blockers).
• Griseofulvin: headache, GI upset, hepatotoxicity, photosensitivity, lupus-like syndrome, teratogenic (avoid in pregnancy and in SLE/porphyria).
• Fluconazole: hepatotoxicity, QT prolongation, CYP2C9/2C19 interactions.^[3]

Pitfalls of treatment choice: treating onychomycosis with topical alone (low cure, long duration, poor penetration); treating moccasin tinea pedis with topical alone (hyperkeratotic sole blocks penetration); not treating the tinea pedis reservoir (recurrence guaranteed); ignoring animal/pet reservoirs (re-infection with M. canis); missing emerging terbinafine resistance in Indian T. mentagrophytes genotype VIII (culture and susceptibility, switch to itraconazole).^[12]

Prognosis & Disposition

Skin tinea (corporis, cruris, pedis, faciei) has an excellent prognosis with appropriate topical therapy — cure rates of 70 to 90% — but recurrence is common if reservoirs (especially tinea pedis), household contacts, and animal contacts are not addressed.^[2]

Tinea capitis has a good prognosis with oral therapy, but kerion may leave scarring alopecia if treatment is delayed, and favus leaves permanent alopecia.^[4]

Onychomycosis has a guarded prognosis — mycological cure 50 to 70% at 12 months, complete cure 35 to 50%, recurrence 20 to 50% (worse for toenails, diabetics, immunosuppressed). Lifelong topical nail lacquer maintenance is sometimes used.^[7][8]

Tinea incognito has a guarded prognosis — chronic, recalcitrant, often requiring prolonged oral therapy; the underlying skin atrophy and telangiectasia may be permanent; HPA-axis suppression may take months to recover.^[10][11]

Predictors of poor prognosis: extensive disease, immunosuppression, diabetes, toenail onychomycosis, tinea incognito, topical steroid misuse, poor adherence, untreated reservoirs (tinea pedis, onychomycosis, household/pet contacts), and emerging terbinafine resistance.^[3]

Disposition: most tinea is managed in primary care; dermatology referral for recalcitrant, extensive, incognito, paediatric capitis, suspected resistance, or immunocompromised patients; urgent primary care or dermatology for kerion (start oral antifungal same day); paediatrics for childhood tinea capitis; podiatry for diabetic onychomycosis; veterinary assessment of pets for M. canis.^[3]

Monitoring on oral therapy: baseline LFTs and U&E; repeat LFTs at 6 weeks for terbinafine/itraconazole; clinical review at end of therapy; re-culture at end of therapy and at 12 months for onychomycosis. Antifungals are discontinued 1 to 2 weeks after clinical resolution for skin disease and after the fixed course for onychomycosis (the dystrophic nail grows out over 12 to 18 months; clinical appearance at end of therapy is not a marker of cure).^[7]

Special Populations

Children — tinea capitis: the commonest dermatophytosis of childhood (peak ages three to seven years; usually T. tonsurans or M. canis). Always systemic (oral) therapy — topical agents alone are not recommended because they do not penetrate the hair follicles within the dermis, though they can reduce spore transmission as adjuncts.^[4] Species guides the drug: terbinafine (about four weeks) is at least as effective as griseofulvin (about eight weeks) for Trichophyton and better for T. tonsurans, while griseofulvin is superior for Microsporum.^[5][6] Adverse-event frequency is similar between the two drugs and severe events are rare.^[5]

Pregnancy: topical azoles and allylamines (clotrimazole 1%, terbinafine 1%) are considered safe. Avoid oral terbinafine especially in the first trimester; griseofulvin and itraconazole are teratogenic and contraindicated. For onychomycosis in pregnancy, defer oral therapy until after delivery; use topical efinaconazole or wait.^[3]

Breastfeeding: topical therapy is preferred. Oral terbinafine is considered compatible with breastfeeding; avoid griseofulvin and itraconazole.^[3]

Diabetes: extensive and recurrent tinea; screen HbA1c in any patient with recurrent tinea. Oral therapy earlier; aggressive treatment of tinea pedis to prevent diabetic foot ulcer and cellulitis; podiatry referral for onychomycosis.^[3]

Immunocompromised (HIV, transplant, chemotherapy, chronic corticosteroid): more extensive, atypical, deeper (Majocchi granuloma, dermal/subcutaneous invasion). Oral therapy from the outset. Lower threshold for biopsy and culture. Check drug interactions with antiretrovirals (terbinafine and itraconazole interact with several PIs and NNRTIs) and calcineurin inhibitors (itraconazole markedly raises tacrolimus/ciclosporin levels). Proximal subungual onychomycosis is an AIDS-defining indicator.^[3]

Elderly: onychomycosis is common; oral therapy requires LFT monitoring and drug-interaction review (polypharmacy). Falls and mobility impact (dystrophic great-toenail impedes gait). High recurrence; topical for limited disease preferred. Screen for peripheral arterial disease and immunosuppression.^[3]

Obese patients: intertriginous tinea cruris and corporis, often with candidal co-infection; oral therapy for extensive disease; weight reduction; antifungal powder (miconazole) in skin folds; treat associated diabetes.^[2]

Patients on warfarin or DOACs: griseofulvin reduces warfarin effect (enzyme induction); itraconazole and fluconazole markedly raise INR (CYP3A4/2C9 inhibition); terbinafine has less interaction. Choose terbinafine and monitor INR closely. For DOACs, itraconazole raises dabigatran/rivaroxaban/apixaban levels — prefer terbinafine.^[3]

Evidence, Guidelines & Regional Differences

Cochrane and meta-analytic evidence dominates the tinea literature: ^[1]

• Cochrane review of systemic antifungal therapy for tinea capitis in children (Chen 2016) — terbinafine and griseofulvin are comparable overall for Trichophyton, terbinafine is superior for T. tonsurans and griseofulvin is superior for Microsporum; complete cure exceeded 90 percent with some interventions but was much lower in many comparisons.^[5]
• Fleece 2004 meta-analysis (Pediatrics) — griseofulvin vs terbinafine for tinea capitis; same species-specific conclusion.^[6]
• Cochrane review of topical treatments for fungal infections of the toenails (Foley 2020) — topical efinaconazole, tavaborole, and ciclopirox outperform vehicle, with high-quality evidence for efinaconazole complete cure, but complete-cure rates with topical treatments are relatively low.^[8]
• Network meta-analysis of toenail onychomycosis monotherapy (Gupta 2020, BJD) — continuous terbinafine 250 mg and continuous itraconazole 200 mg have significantly greater odds of mycological cure than topical treatments; fluconazole and pulse regimens did not differ significantly from other options.^[7]
• Cochrane review of oral treatments for fungal infections of the skin of the foot (Bell-Syer 2012) — terbinafine is more effective than griseofulvin at curing tinea pedis (pooled risk ratio 2.26), and terbinafine and itraconazole are more effective than no treatment; oral therapy is usually reserved for chronic disease or failed topical treatment.^[9]

Regional guideline differences are shown in the Region block above. The pivotal regional issue is the Indian epidemic of tinea incognito driven by the AAA syndrome — addressed by IADVL consensus, the Indian Drugs Act restrictions on fixed-dose corticosteroid-antifungal-antibacterial creams, pharmacist education, and emerging antifungal stewardship programs.^[10][11][12]

Emerging terbinafine resistance in the Trichophyton mentagrophytes species complex — now termed Trichophyton indotineae — is a major contemporary controversy that emerged in India and is spreading globally. Resistance is predominantly associated with point mutations in the squalene epoxidase (SQLE/ERG1) gene, most commonly Phe397Leu (often together with Ala448Thr), with high-level resistance frequent in resistant clones. Management hinges on species identification by ITS sequencing, culture and antifungal susceptibility testing, and prioritising non-terbinafine options for resistant disease.^[14]

Griseofulvin shortages (Bonifaz 2024, Expert Review of Anti-infective Therapy) — in countries where griseofulvin is no longer available, itraconazole (3 to 4 weeks for Trichophyton; 6 to 8 weeks for Microsporum) and terbinafine (Trichophyton only) are the substitutes, with species-guided choice critical.^[13]

Controversies: the role of combination topical + oral therapy in severe disease (no clear evidence of superiority over oral alone; reserved for extensive/recalcitrant); prophylactic antifungal in recurrent onychomycosis (limited evidence; topical efinaconazole maintenance and chemical nail avulsion sometimes used); adjunct oral corticosteroid in kerion (observational evidence only; reduces pain and probably scarring but not infection duration); length of terbinafine therapy for toenail onychomycosis (12 weeks standard; 6 months with doubtful added benefit).^[3][4]

Exam Pearls

^[1]

References14ShowHide

1. [1]Leung AK, Lam JM, Leong KF. Tinea corporis: an updated review Drugs Context, 2020.PMID 32742295
2. [2]Sahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review Indian Dermatol Online J, 2016.PMID 27057486
3. [3]Caplan AS, Gold JAW, Smith DJ. Diagnosis and Management of Tinea Infections Am Fam Physician, 2025.PMID 41118183
4. [4]Leung AKC, Hon KL, Leong KF. Tinea Capitis: An Updated Review Recent Pat Inflamm Allergy Drug Discov, 2020.PMID 31906842
5. [5]Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children Cochrane Database Syst Rev, 2016.PMID 27169520
6. [6]Fleece D, Gaughan JP, Aronoff SC. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials Pediatrics, 2004.PMID 15520113
7. [7]Gupta AK, Foley KA, Mays RR, et al. Monotherapy for toenail onychomycosis: a systematic review and network meta-analysis Br J Dermatol, 2020.PMID 31120134
8. [8]Foley K, Gupta AK, Versteeg S. Topical and device-based treatments for fungal infections of the toenails Cochrane Database Syst Rev, 2020.PMID 31978269
9. [9]Bell-Syer SE, Khan SM, Torgerson DJ. Oral treatments for fungal infections of the skin of the foot Cochrane Database Syst Rev, 2012.PMID 23076898
10. [10]Dutta B, Rasul ES, Boro B. Clinico-epidemiological study of tinea incognito with microbiological correlation Indian J Dermatol Venereol Leprol, 2017.PMID 28366916
11. [11]Thakran P, Agrawal S, Singal A, Verma S, Madhu SV. Iatrogenic Cushing's Syndrome in Patients with Superficial Dermatophytosis Indian Dermatol Online J, 2021.PMID 33959519
12. [12]Verma SB, Vasani R. Male genital dermatophytosis - clinical features and the effects of the misuse of topical steroids and steroid combinations - an alarming problem in India Mycoses, 2016.PMID 27028087
13. [13]Bonifaz A, Lumbán-Ramírez P, García-Sotelo RS, et al. Now that griseofulvin is not available, what to do with tinea capitis treatments? Expert Rev Anti Infect Ther, 2024.PMID 39297581
14. [14]Aboutalebian S, Jahanshiri Z, Kharazi M, et al. Multicenter study reveals alarming terbinafine resistance in Trichophyton indotineae isolates from Iran Med Mycol, 2026.PMID 42329781